Phase II study of resection of primary colorectal caner and synchronous liver metastasis after S-1 + oxaliplatin (SOX) + Bevacizumab(Bmab) therapy and adjuvant S-1 chemotherapy - Study of resection of primary colorectal caner and synchronous liver metastasis after SOX + Bmab

Aomori Colorectal Cancer Study (ACCS) group0 sites28 target enrollmentStarted: April 4, 2018Last updated: October 17, 2023

Overview

No summary available.

•"1\) with gastrointestinal ulceration or bleeding 2\) with sensory neuropathy 3\) with severe diarrhea 4\) had a previous serious drug allergies 5\) had pleural effusion or ascites which need therapy 6\) with brain metastasis or suspected the brain metastases 7\) had surgery within 28 days before registration 8\) had thromboembolism, cerebral infarction, pulmonary infarction, interstitial pneumonia 9\) had serious complication (e.g. interstitialpneumonia, or pulmonary fibrosis, kidney injury, hepatic failure, uncontrolled diabetes mellitus, uncontrolled hypertension) 10\) with active double cancer 11\) had active infection disease (over 38\.0 degree) 12\) with significant abnormal electrocardiogram or cardiovascular disease (e.g. heart failure, myocardial infarction, angina pectoris) 13\) receiving Flucytosine 14\) pregnant or lactating women, women who are capable of pregnancy, intend to get pregnant or men who want to get their partners pregnant 15\) had hemoptysis (2\.5 ml or more of fresh blood) 16\) had gastrointestinal perforation within 6 months 17\) were systemically\-administered of steroids 18\) with contraindications to TS\-1, L\-OHP, and Bevacizumab 19\) with HBsAg\-positive 20\) Physician will determine that the patient is inappropriate participate in this trail for the safety. "

Sponsor

Aomori Colorectal Cancer Study (ACCS) group